{"url":"https://lda.senate.gov/api/v1/filings/e475399b-2d2e-4e7a-b77a-c09a66f5a310/","filing_uuid":"e475399b-2d2e-4e7a-b77a-c09a66f5a310","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2025,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/e475399b-2d2e-4e7a-b77a-c09a66f5a310/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Richard M. Gold, Partner","dt_posted":"2025-10-15T13:43:02-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"800 17th Street NW","registrant_address_2":"Suite 1100","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20006","registrant":{"id":18466,"url":"https://lda.senate.gov/api/v1/registrants/18466/","house_registrant_id":30825,"name":"HOLLAND & KNIGHT LLP","description":"Law Firm","address_1":"800 17th Street NW","address_2":"Suite 1100","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"RICHARD GOLD","contact_telephone":"+1 202-955-3000","dt_updated":"2026-01-29T12:53:12.839213-05:00"},"client":{"id":63462,"url":"https://lda.senate.gov/api/v1/clients/63462/","client_id":63462,"name":"ACADIA PHARMACEUTICALS INC.","general_description":"Biopharmaceutical company","client_government_entity":null,"client_self_select":false,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2024-11-12"},"lobbying_activities":[{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax Reform - Restoring the Orphan Drug Tax Credit.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":139756,"prefix":"mr","prefix_display":"MR.","first_name":"JOSHUA","nickname":null,"middle_name":"DAVID","last_name":"ODINTZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152318,"prefix":"mr","prefix_display":"MR.","first_name":"ANDREW","nickname":null,"middle_name":"JOSEPH","last_name":"SIRACUSE","suffix":null,"suffix_display":null},"covered_position":"Sr. Tax Cnsl., Sen. John Cornyn; Staff Dir., Sen. Fin. Cmte. Int'l. Trade, Customs & Global Comp. Sbcmte., Tax Cnsl., Sen. Cornyn; Cnsl. Sen. Cornyn; Staff Dir. Sen. Fin. Cmte, Energy, Nat. Res. Sbcmte.; LA, Sen. Cornyn; LA, Sen. Norm Coleman","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}